Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 3, 2023Cancer DiscoveryOpen Access

Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

CAClare M. AdamsUniversity of SienaRMRamkrishna MitraThomas Jefferson UniversityYXYou‐Cai XiaoNational Medical Products Administration

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Adams et al. (2023) studied this question.

synapsesocial.com/papers/69d7e4c3ec32c73b01ae338ehttps://doi.org/10.1158/2159-8290.cd-22-1131
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs2019 · 3,548 citations
  2. 2MDM2 mediates p73 ubiquitination: a new molecular mechanism for suppression of p73 function2015 · 44 citations
  3. 3Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development2013 · 392 citations
  4. 4Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells2015 · 31 citations